Application of beta-NMN in preparation of medicament for treatment and prevention of organ damage caused by sepsis

Abstract

The invention relates to application of beta-nicotinamide mononucleotide (NMN) in the preparation of a medicament for treatment and / or prevention of organ damage caused by sepsis. The invention discloses a novel application of the beta-NMN. The beta-NMN has treatment and prevention protection effects on multiple organ damage caused by sepsis, thereby providing a novel treatment means and a noveltreatment way for diseases in related fields, moreover, the beta-NMN is easily soluble in water, has strong universality and operability, and can be administered in various ways.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the application of β-NMN in the preparation of medicines for the treatment and prevention of sepsis organ damage. Background technique [0002] Sepsis is a life-threatening multiple organ dysfunction caused by an imbalanced body response after infection, which can develop into septic shock and multiple organ dysfunction syndrome (MODS). One of the leading causes of death among patients. According to reports, there are nearly 18 million sepsis patients in the world every year, and the annual number of sepsis patients in my country is estimated to be more than 5 million, and the number of patients is increasing at a rate of nearly 10% year by year, causing a serious medical burden. The research data of scholars at home and abroad show that despite the continuous progress of "bundle" treatment strategies such as volume assessment and resuscitation, early anti-infection and organ support,...

AI Technical Summary

Problems solved by technology

The current evidence does not support the use of antibiotics within a strict time window for all patients with sepsis, and the overuse of antibiotics will also lead to the increase of drug resistance

[0007] 4. Other adjuvant treatment methods: patients with severe sepsis need to use high-flow nasal cannula or mask oxygen inhalation to protect ventilation to treat respiratory distress and hypoxemia; when the blood glucose level of the patient exceeds 180mg / dl continuously, then Insulin is required, but capillary blood glucose levels detected by bedside indicators do not adequately reflect the patient's plasma and arterial blood glucose

Recent research by the inventor's team confirms that the application of nicotinamide riboside improves NAD + The content can effectively reduce the damage of major organs in sepsis, but it needs to be administered prophylactically before the onset of sepsis, such as giving nicotinamide riboside after the onset of sepsis does not have any protective effect, the reason is that the sepsis condition Severely reduces the expression of nicotinamide riboside kinase, resulting in the inability of nicotinamide riboside to be converted to β-nicotinamide mononucleotide in vivo (Hong G, et al. Free Radiac Bio Med 2018; 123:125-137)

Therefore, nicotinamide riboside is unlikely to be used in the treatment of major organ damage in sepsis

Images